New drug VEGF Trap-Eye – Eylea – and its use in the treatment of age-related 
macular degeneration, central retinal vein occlusion, diabetic macular edema, 
and choroidal neovascularization secondary to pathologic myopia

Robert Rejdak; Małgorzata Szkaradek; Wesam Taslaq; Jakub Kałużny; Paweł Grieb; Anselm Jünemann

Abstract

4/2012 vol. 114

Review article

New drug VEGF Trap-Eye – Eylea – and its use in the treatment of age-related macular degeneration, central retinal vein occlusion, diabetic macular edema, and choroidal neovascularization secondary to pathologic myopia

Robert Rejdak ^{1, 2}

,

Małgorzata Szkaradek ²

,

Wesam Taslaq ²

,

Jakub J. Kałużny ³

,

Paweł Grieb ⁴

,

Anselm G. M. Jünemann ⁵

Klinika Okulistyki Ogólnej, Katedra Okulistyki Uniwersytetu Medycznego w Lublinie
Oddział Okulistyki Wojewódzkiego Szpitala Specjalistycznego im. F. Chopina w Rzeszowie
Katedra Zdrowia Publicznego Collegium Medicum w Bydgoszczy Uniwersytetu Mikołaja Kopernika w Toruniu
Zakład Farmakologii Doświadczalnej Instytutu Medycyny Doświadczalnej i Klinicznej Polskiej Akademii Nauk w Warszawie
Klinik für Augenheilkunde, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen – Nürnberg, Erlangen

Online publish date: 2012/12/12

View full text

AMA

Rejdak R, Szkaradek M, Taslaq W, Kałużny JJ, Grieb P, Jünemann AG. New drug VEGF Trap-Eye – Eylea – and its use in the treatment of age-related macular degeneration, central retinal vein occlusion, diabetic macular edema, and choroidal neovascularization secondary to pathologic myopia. Klinika Oczna / Acta Ophthalmologica Polonica. 2012;114(4):308-310.

APA

Rejdak, R., Szkaradek, M., Taslaq, W., Kałużny, J. J., Grieb, P., & Jünemann, A. G. (2012). New drug VEGF Trap-Eye – Eylea – and its use in the treatment of age-related macular degeneration, central retinal vein occlusion, diabetic macular edema, and choroidal neovascularization secondary to pathologic myopia. Klinika Oczna / Acta Ophthalmologica Polonica, 114(4), 308-310.

Chicago

Rejdak, Robert, Małgorzata Szkaradek, Wesam Taslaq, Jakub J Kałużny, Paweł Grieb, and Anselm G Jünemann. 2012. "New drug VEGF Trap-Eye – Eylea – and its use in the treatment of age-related macular degeneration, central retinal vein occlusion, diabetic macular edema, and choroidal neovascularization secondary to pathologic myopia". Klinika Oczna / Acta Ophthalmologica Polonica 114 (4): 308-310.

Harvard

Rejdak, R., Szkaradek, M., Taslaq, W., Kałużny, J., Grieb, P., and Jünemann, A. (2012). New drug VEGF Trap-Eye – Eylea – and its use in the treatment of age-related macular degeneration, central retinal vein occlusion, diabetic macular edema, and choroidal neovascularization secondary to pathologic myopia. Klinika Oczna / Acta Ophthalmologica Polonica, 114(4), pp.308-310.

MLA

Rejdak, Robert et al. "New drug VEGF Trap-Eye – Eylea – and its use in the treatment of age-related macular degeneration, central retinal vein occlusion, diabetic macular edema, and choroidal neovascularization secondary to pathologic myopia." Klinika Oczna / Acta Ophthalmologica Polonica, vol. 114, no. 4, 2012, pp. 308-310.

Vancouver

Rejdak R, Szkaradek M, Taslaq W, Kałużny J, Grieb P, Jünemann A. New drug VEGF Trap-Eye – Eylea – and its use in the treatment of age-related macular degeneration, central retinal vein occlusion, diabetic macular edema, and choroidal neovascularization secondary to pathologic myopia. Klinika Oczna / Acta Ophthalmologica Polonica. 2012;114(4):308-310.

Vascular endothelial growth factor (VEGF) plays an important role in the pathogenesis of choroidal and retinal neovascularization. Anti-VEGF therapy changed the standard-of-care for ocular disease with neovascularisation. This article presents one promising new drug – VEGF Trap-Eye – and results of clinical trials evaluating its efficacy in the treatment of wet age-related macular degeneration, central retinal vain occlusion, diabetic macular edema and choroidal neovascularization secondary to pathologic myopia.

Keywords

vascular endothelial growth factor, VEGF Trap-Eye, Eylea, neovascularization

Abstract

New drug VEGF Trap-Eye – Eylea – and its use in the treatment of age-related macular degeneration, central retinal vein occlusion, diabetic macular edema, and choroidal neovascularization secondary to pathologic myopia

Keywords

Share

Integrated with

Editorial Policies